ORIONS Money Stocks

[Volcano]

Big news coming this week!
Fasten your seat belt

Capricor Therapeutics to Present One-Year Efficacy Results from its Ongoing HOPE-2 Open Label Extension Study at 2022 Parent Project Muscular Dystrophy Annual Conference
Mentioned: CAPR
EQNX::TICKER_START (NASDAQ:CAPR), EQNX::TICKER_END Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, today announced that the Company will present one-year, safety and efficacy results from its HOPE-2 open-label extension study with lead asset CAP-1002 for treating Duchenne muscular dystrophy (DMD) at this year's Parent Project Muscular Dystrophy (PPMD) Annual Conference.